Lipoprotein lipase activity determined in vivo is lower in carriers of apolipoprotein A-V gene variants 19W and -1131C

Physiological Research

Volumn 57, Issue 4, 2008, Pages 555-561

  Kovar J ^a,b   Adamkova V ^a  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^b Centre for Experimental Cardiovascular Research   (Czech Republic)

Author keywords

Apolipoprotein A V; Genetics; Lipoprotein lipase; Nonesterified fatty acids

Indexed keywords

APOA5 PROTEIN, HUMAN; APOLIPOPROTEIN A; FATTY ACID; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

AGING; ARTICLE; BLOOD; BODY MASS; FAT INTAKE; FEMALE; GENETIC VARIABILITY; GENETICS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HETEROZYGOTE; HUMAN; MALE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; WAIST HIP RATIO;

AGING; APOLIPOPROTEINS A; BLOOD GLUCOSE; BODY MASS INDEX; DIETARY FATS; FATTY ACIDS, NONESTERIFIED; FEMALE; GLUCOSE TOLERANCE TEST; HETEROZYGOTE; HUMANS; LIPOPROTEIN LIPASE; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; MALE; MIDDLE AGED; TRIGLYCERIDES; VARIATION (GENETICS); WAIST-HIP RATIO;

EID: 50449107665     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. CÍFKOVÁ R, ŠKODOVÁ Z: Longitudinal trends in major cardiovascular disease risk factors in the Czech population. (in Czech) Čas Lék Čes 143: 219-226, 2004.
2. FRUCHART-NAJIB J, BAUGE E, NICULESCU LS, PHAM T, THOMAS B, ROMMENS C, MAJD Z, BREWER B, PENNACCHIO LA, FRUCHART JC: Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5. Biochem Biophys Res Commun 319: 397-404, 2004.
3. GLANTZ SA: Primer of Biostatistics. McGraw-Hill, New York, 1992.
4. HAVEL RJ, EDER HA, BRAGDON JH: The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34: 1345-1353, 1955.
5. HOLZL B, IGLSEDER B, SANDHOFER A, MALAIMARE L, LANG J, PAULWEBER B, SANDHOFER F: Insulin sensitivity is impaired in heterozygous carriers of lipoprotein lipase deficiency. Diabetologia 45: 378-384, 2002.
6. HOŘÍNEK A, VRABLÍK M, ČEŠKA R, ADÁMKOVÁ V, POLEDNE R, HUBÁČEK JA: T-1131 - >C polymorphism within the apolipoprotein AV gene in hypertriglyceridemic individuals. Atherosclerosis 167: 369-370, 2003.
7. HUBÁČEK JA, ŠKODOVÁ Z, ADÁMKOVÁ V, LÁNSKÁ V, POLEDNE R: The influence of APOAV polymorphisms (T-1131>C and S19>W) on plasma triglyceride levels and risk of myocardial infarction. Clin Genet 65: 126-130, 2004.
8. JINDŘICHOVÁ E, KRATOCHVÍLOVÁ S, KOVÁŘ J: Glucose administration downregulates lipoprotein lipase activity in vivo: a study using repeated intravenous fat tolerance test. Physiol Res 56: 175-181, 2007.
9. PENNACCHIO LA, OLIVIER M, HUBACEK JA, COHEN JC, COX DR, FRUCHART JC, KRAUSS RM, RUBIN EM: An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 294: 169-173, 2001.
10. PENNACCHIO LA, OLIVIER M, HUBÁČEK JA, KRAUSS RM, RUBIN EM, COHEN JC: Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels. Hum Mol Genet 11: 3031-3038, 2002.
11. MERKEL M, LOEFFLER B, KLUGER M, FABIG N, GEPPERT G, PENNACCHIO LA, LAATSCH A, HEEREN J: Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. J Biol Chem 280: 21553-21560, 2005.
12. RÖSSNER S: Studies on an intravenous fat tolerance test. Methodological, experimental and clinical experiences with Intralipid. Acta Med Scand Suppl 564: 1-24, 1974.
13. ŠEDA O, ŠEDOVÁ L: New apolipoprotein A-V: comparative genomics meets metabolism. Physiol Res 52: 141-146, 2003.
14. SCHAAP FG, RENSEN PC, VOSHOL PJ, VRINS C, VAN DER VLIET HN, CHAMULEAU RA, HAVEKES LM, GROEN AK, VAN DIJK KW: ApoAV reduces plasma triglycerides by inhibiting very low density lipoproteintriglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. J Biol Chem 279: 27941-27947, 2004.
15. TALMUD PJ, PALMEN J, PUTT W, LINS L, HUMPHRIES SE: Determination of the functionality of common APOA5 polymorphisms. J Biol Chem 280: 28215-28220, 2005.
16. VAN DER VLIET HN, SAMMELS MG, LEEGWATER AC, LEVELS JH, REITSMA PH, BOERS W, CHAMULEAU RA: Apolipoprotein A-V: a novel apolipoprotein associated with an early phase of liver regeneration. J Biol Chem 276: 44512-44520, 2001.
17. VRABLÍK M, HOŘÍNEK A, ČEŠKA R, ADÁMKOVÁ V, POLEDNE R, HUBÁČEK JA: Ser19 - >Trp polymorphism within the apolipoprotein AV gene in hypertriglyceridaemic people. J Med Genet 40: e105, 2003.
18. WATERWORTH DM, TALMUD PJ, LUAN J, FLAVELL DM, BYRNE CD, HUMPHRIES SE, WAREHAM NJ: Variants in the APOC3 promoter insulin responsive element modulate insulin secretion and lipids in middle-aged men. Biochim Biophys Acta 1637: 200-206, 2003.
19. WEINBERG RB, COOK VR, BECKSTEAD JA, MARTIN DD, GALLAGHER JW, SHELNESS GS, RYAN RO: Structure and interfacial properties of human apolipoprotein A-V. J Biol Chem 278: 34438-34444, 2003.